New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data
1. LLY and NVO plan oral obesity drugs at injectable prices. 2. Political pressure pushes for more affordable weight-loss medications. 3. LLY stockpiled $808.5 million of orforglipron ahead of launch. 4. Analysts predict comparable pricing to existing injectable options. 5. Disappointing weight loss results from LLY's orforglipron data.